{"filing":{"accession_number":"0001689548-26-000082","cik":"0001689548","ticker":"PRAX","company_name":"Praxis Precision Medicines, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"prax-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/prax-20260806.htm"},"events":[{"id":25948,"run_id":23562,"accession_number":"0001689548-26-000082","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"Praxis Precision Medicines reported Q2 2026 financial results, including R\u0026D expenses of $69.4M, G\u0026A expenses of $27.5M, a net loss of $83.7M, and a cash position of $1.4B as of June 30, 2026. The disclosure includes operational highlights and anticipated milestones for the company's drug development programs, providing investors with visibility into the company's financial performance and cash runway into 2028.","company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26896,"accession_number":"0001689548-26-000082","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses quarterly financial results including R\u0026D expenses ($69.4M), G\u0026A expenses ($27.5M), net loss ($83.7M), and cash position ($1.4B as of June 30, 2026), along with operational highlights and anticipated milestones for the company's drug development programs. The disclosure is material as it provides investors with the company's financial performance and cash runway guidance into 2028.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:49:09.644820+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26897,"accession_number":"0001689548-26-000082","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses second quarter 2026 financial results for Praxis Precision Medicines, including R\u0026D expenses ($69.4M), G\u0026A expenses ($27.5M), net loss ($83.7M), cash position ($1.4B), and share count (27.9M shares). The press release (EX-99.1) explicitly states \"Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results\" and includes detailed financial metrics and operational highlights. This is a standard quarterly earnings disclosure material to investors assessing the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:49:09.644820+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26896,"accession_number":"0001689548-26-000082","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses quarterly financial results including R\u0026D expenses ($69.4M), G\u0026A expenses ($27.5M), net loss ($83.7M), and cash position ($1.4B as of June 30, 2026), along with operational highlights and anticipated milestones for the company's drug development programs. The disclosure is material as it provides investors with the company's financial performance and cash runway guidance into 2028.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:49:09.644820+00:00","company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","filing_date":"2026-08-06"},{"id":26897,"accession_number":"0001689548-26-000082","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses second quarter 2026 financial results for Praxis Precision Medicines, including R\u0026D expenses ($69.4M), G\u0026A expenses ($27.5M), net loss ($83.7M), cash position ($1.4B), and share count (27.9M shares). The press release (EX-99.1) explicitly states \"Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results\" and includes detailed financial metrics and operational highlights. This is a standard quarterly earnings disclosure material to investors assessing the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:49:09.644820+00:00","company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","filing_date":"2026-08-06"}]}